Published in Biotech Business Week, November 24th, 2008
"In addition, based on measurements of disease activity or a marker of cartilage degradation (CTX-II), treatment adjustments...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.